1 es for the development of an affordable anti-
Chagasic agent.
2 may facilitate the development of novel anti-
Chagasic agents.
3 The oxidative stress in both
chagasic animals and animals with ethanol-induced cardio
4 Thus, NA restores Ito in
chagasic canine epicardial myocytes.
5 Chagasic cardiomyopathy (CC) is the most frequent nonisc
6 may provide insight into the pathogenesis of
chagasic cardiomyopathy and provide new targets for inte
7 Managing arrhythmias in patients with
Chagasic cardiomyopathy is a major challenge for the cli
8 cruzi, is a leading cause of heart disease ("
chagasic cardiomyopathy") in Latin America, disproportio
9 intracellular protozoan parasite that causes
Chagasic cardiomyopathy, elicits a robust hypertrophic r
10 Patients 18 to 75 years of age with chronic
chagasic cardiomyopathy, New York Heart Association clas
11 Chronic
chagasic cardiomyopathy, the most devastating manifestat
12 ic oxide synthase (iNOS) expression in acute
Chagasic cardiomyopathy, we studied a rat model of acute
13 hanisms underlying the pathogenesis of acute
chagasic cardiomyopathy.
14 soma cruzi is the causative agent of chronic
chagasic cardiomyopathy.
15 or quality of life in patients with chronic
chagasic cardiomyopathy.
16 randomized trial of BMNC therapy in chronic
chagasic cardiomyopathy.
17 s (BMNCs) improves heart function in chronic
chagasic cardiomyopathy.
18 anges in the myocardium of a murine model of
chagasic cardiomyopathy.
19 derived ET-1, in the pathogenesis of chronic
Chagasic cardiomyopathy.
20 ested as contributing to the pathogenesis of
Chagasic cardiomyopathy.
21 f pathways involved in cardiac remodeling in
chagasic cardiomyopathy.
22 participate in the pathophysiology of acute
Chagasic cardiomyopathy.
23 hagas disease, with most patients developing
Chagasic cardiomyopathy.
24 impact generally in the heart in the form of
chagasic cardiomyopathy.
25 ents at different clinical stages of chronic
chagasic heart disease.
26 its parasite proliferation but may result in
chagasic heart disease.
27 dative stress-induced injurious processes in
chagasic heart dysfunction.
28 production, and energy homeostasis in acute
chagasic hearts.
29 of conventional HF therapies, patients with
Chagasic HF with reduced ejection fraction continue to h
30 There were 195 patients with
Chagasic HF with reduced ejection fraction, 1300 with ot
31 DESIGN, SETTING, AND PARTICIPANTS:
CHAGASICS is an open-label, randomized clinical trial.
32 re significantly reduced in TcVac2-immunized
chagasic mice.
33 ontrol of parasite burden and myocarditis in
chagasic mice.
34 abolic decay and energy homeostasis in acute
chagasic myocarditis and further suggest that oxidative
35 results suggest that the reduction of Ito in
chagasic myocytes during the acute stage of Chagas' dise
36 7.2, 12.5, and 11.4 per 100 person-years for
Chagasic,
other nonischemic, and ischemic patients, resp
37 tigator-reported etiology was categorized as
Chagasic,
other nonischemic, or ischemic cardiomyopathy.
38 , bears primary responsibility for producing
chagasic pathology.
39 Chronic
chagasic patients (CCPs) have dysfunctional CD8(+) T cel
40 deep sequencing to analyze this diversity in
chagasic patients from Mexico.
41 Chagasic patients presented a diverse assemblage of para
42 Compared with other etiologies,
Chagasic patients were more often female, younger, and h
43 evels of IL-7 were also increased in chronic
chagasic patients.
44 esence of the parasite in the bloodstream of
chagasic patients.
45 d efficacy gaps of current drug treatment in
Chagasic patients.
46 contributed to declining cardiac function in
chagasic rats.
47 function was prevented in PBN +/- BZ-treated
chagasic rats.
48 ative pathology and chronic heart failure in
chagasic rats.
49 multispecific high-affinity IgG from chronic
chagasic sera and on sodium dodecyl sulfate-polyacrylami
50 confidence interval, 1.15-1.94; P=0.003) and
Chagasic versus ischemic: 1.55 (1.18-2.04; P=0.002).
51 ents, respectively-adjusted hazard ratio for
Chagasic versus other nonischemic: 1.49 (95% confidence